Unknown

Dataset Information

0

Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial.


ABSTRACT: PURPOSE:This open-label phase III trial evaluated efficacy and tolerability of linifanib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC) without prior systemic therapy. PATIENTS AND METHODS:Patients were randomly assigned in a 1:1 ratio to linifanib 17.5 mg once daily or sorafenib 400 mg twice daily. Patients were stratified by region (Outside Asia, Japan, and rest of Asia), Eastern Cooperative Oncology Group performance score (ECOG PS; 0 or 1), vascular invasion or extrahepatic spread (yes or no), and hepatitis B virus (HBV) infection (yes or no). The primary end point of the study was overall survival (OS). Secondary end points were time to progression (TTP) and objective response rate (ORR) per RECIST v1.1. RESULTS:We randomly assigned 1,035 patients (median age, 60 years; Asian, 66.6%; ECOG PS 0, 65.2%; HBV, 49.1%; vascular invasion or extrahepatic spread, 70.1%). Median OS was 9.1 months on the linifanib arm (95% CI, 8.1 to 10.2) and 9.8 months on the sorafenib arm (95% CI, 8.3 to 11.0; hazard ratio [HR], 1.046; 95% CI, 0.896 to 1.221). For prespecified stratification subgroups, OS HRs ranged from 0.793 to 1.119 and the 95% CI contained 1.0. Median TTP was 5.4 months on the linifanib arm (95% CI, 4.2 to 5.6) and 4.0 months on the sorafenib arm (95% CI, 2.8 to 4.2; HR, 0.759; 95% CI, 0.643 to 0.895; P = .001). Best response rate was 13.0% on the linifanib arm versus 6.9% on the sorafenib arm. Grade 3/4 adverse events (AEs); serious AEs; and AEs leading to discontinuation, dose interruption, and reduction were more frequent with linifanib (all P < .001). CONCLUSION:Linifanib and sorafenib had similar OS in advanced HCC. Predefined superiority and noninferiority OS boundaries were not met for linifanib and the study failed to meet the primary end point. TTP and ORR favored linifanib; safety results favored sorafenib.

SUBMITTER: Cainap C 

PROVIDER: S-EPMC4279237 | biostudies-literature | 2015 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial.

Cainap Calin C   Qin Shukui S   Huang Wen-Tsung WT   Chung Ik Joo IJ   Pan Hongming H   Cheng Ying Y   Kudo Masatoshi M   Kang Yoon-Koo YK   Chen Pei-Jer PJ   Toh Han-Chong HC   Gorbunova Vera V   Eskens Ferry A L M FA   Qian Jiang J   McKee Mark D MD   Ricker Justin L JL   Carlson Dawn M DM   El-Nowiem Saied S  

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20141208 2


<h4>Purpose</h4>This open-label phase III trial evaluated efficacy and tolerability of linifanib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC) without prior systemic therapy.<h4>Patients and methods</h4>Patients were randomly assigned in a 1:1 ratio to linifanib 17.5 mg once daily or sorafenib 400 mg twice daily. Patients were stratified by region (Outside Asia, Japan, and rest of Asia), Eastern Cooperative Oncology Group performance score (ECOG PS; 0 or 1), vascular  ...[more]

Similar Datasets

| S-EPMC5091321 | biostudies-literature
| S-EPMC5100089 | biostudies-literature
| S-EPMC6794885 | biostudies-literature
| S-EPMC3639524 | biostudies-literature
| S-EPMC3796498 | biostudies-literature
| S-EPMC5985414 | biostudies-literature
| S-EPMC7548914 | biostudies-literature
| S-EPMC7475472 | biostudies-literature
| S-EPMC4056058 | biostudies-literature
| S-EPMC5016063 | biostudies-literature